FindTrial
Sign In

Expanded Access to RXDX-105 for Cancers With RET Alterations

Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03052569
Enrollment
Unknown
Registered
2017-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2019-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancers With RET Alterations

Brief summary

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Interventions

DRUGRXDX-105

Oral Capsules

Sponsors

Hoffmann-La Roche
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Diagnosis of advanced cancer with RET alterations * Unable to participate in an ongoing RXDX-105 clinical trial * Willing and able to provide written, signed informed consent * Medically suitable for treatment with RXDX-105

Exclusion criteria

* Prior treatment with a TKI that has activity against RET alterations * Currently enrolled in an ongoing clinical study with any other investigational agent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026